Processa Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.2851
- Today's High:
- $0.33
- Open Price:
- $0.3046
- 52W Low:
- $0.251
- 52W High:
- $2.68
- Prev. Close:
- $0.29
- Volume:
- 52758
Company Statistics
- Market Cap.:
- $9.03 million
- Book Value:
- 0.373
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -73.54%
- Return on Equity TTM:
- -175.55%
Company Profile
Processa Pharmaceuticals Inc had its IPO on 2017-10-10 under the ticker symbol PCSA.
The company operates in the Healthcare sector and Biotechnology industry. Processa Pharmaceuticals Inc has a staff strength of 15 employees.
Stock update
Shares of Processa Pharmaceuticals Inc opened at $0.3 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.29 - $0.33, and closed at $0.3.
This is a +3.21% increase from the previous day's closing price.
A total volume of 52,758 shares were traded at the close of the day’s session.
In the last one week, shares of Processa Pharmaceuticals Inc have slipped by -10.66%.
Processa Pharmaceuticals Inc's Key Ratios
Processa Pharmaceuticals Inc has a market cap of $9.03 million, indicating a price to book ratio of 1.8273 and a price to sales ratio of 0.
In the last 12-months Processa Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-17888330. The EBITDA ratio measures Processa Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Processa Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -73.54% with a return of equity of -175.55%.
In Q2, Processa Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Processa Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.31 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Processa Pharmaceuticals Inc’s profitability.
Processa Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3022. Its price to sales ratio in the trailing 12-months stood at 0.
Processa Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.09 million
- Total Liabilities
- $821414.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Processa Pharmaceuticals Inc ended 2024 with $10.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.09 million while shareholder equity stood at $9.16 million.
Processa Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $821414.00 in other current liabilities, 2463.00 in common stock, $-70882199.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.68 million and cash and short-term investments were $8.68 million. The company’s total short-term debt was $81,890 while long-term debt stood at $0.
Processa Pharmaceuticals Inc’s total current assets stands at $9.90 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $239022.00 and inventory worth $0.
In 2024, Processa Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Processa Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.3
- 52-Week High
- $2.68
- 52-Week Low
- $0.251
- Analyst Target Price
- $3
Processa Pharmaceuticals Inc stock is currently trading at $0.3 per share. It touched a 52-week high of $2.68 and a 52-week low of $2.68. Analysts tracking the stock have a 12-month average target price of $3.
Its 50-day moving average was $0.4 and 200-day moving average was $0.75 The short ratio stood at 1.41 indicating a short percent outstanding of 0%.
Around 1622.6% of the company’s stock are held by insiders while 653.4% are held by institutions.
Frequently Asked Questions About Processa Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytidine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.